JP2020002019A5 - - Google Patents

Download PDF

Info

Publication number
JP2020002019A5
JP2020002019A5 JP2018120081A JP2018120081A JP2020002019A5 JP 2020002019 A5 JP2020002019 A5 JP 2020002019A5 JP 2018120081 A JP2018120081 A JP 2018120081A JP 2018120081 A JP2018120081 A JP 2018120081A JP 2020002019 A5 JP2020002019 A5 JP 2020002019A5
Authority
JP
Japan
Prior art keywords
cell proliferation
cells
cck
calculated
comparative example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018120081A
Other languages
Japanese (ja)
Other versions
JP2020002019A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2018120081A priority Critical patent/JP2020002019A/en
Priority claimed from JP2018120081A external-priority patent/JP2020002019A/en
Publication of JP2020002019A publication Critical patent/JP2020002019A/en
Publication of JP2020002019A5 publication Critical patent/JP2020002019A5/ja
Priority to JP2022072979A priority patent/JP7463429B2/en
Pending legal-status Critical Current

Links

Description

0.2%FBS含有培地処理群(比較例6−1)の細胞数を基準とし、細胞数から細胞増殖促進率を算出した(表6)。ここで、CCK−8細胞増殖率は、以下のようにして計算される。
<CCK−8による細胞増殖促進率(%)>
=((各実施例における細胞数/比較例6−1における細胞数)−1)×100
The cell proliferation promotion rate was calculated from the number of cells based on the number of cells in the 0.2% FBS-containing medium-treated group (Comparative Example 6-1) (Table 6). Here, the CCK-8 cell proliferation rate is calculated as follows.
<Cell proliferation promotion rate by CCK-8 (%)>
= ((Number of cells in cell number / Comparative Example 6-1 in each example) -1) × 100

JP2018120081A 2018-06-25 2018-06-25 Oral composition Pending JP2020002019A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018120081A JP2020002019A (en) 2018-06-25 2018-06-25 Oral composition
JP2022072979A JP7463429B2 (en) 2018-06-25 2022-04-27 Oral Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018120081A JP2020002019A (en) 2018-06-25 2018-06-25 Oral composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022072979A Division JP7463429B2 (en) 2018-06-25 2022-04-27 Oral Composition

Publications (2)

Publication Number Publication Date
JP2020002019A JP2020002019A (en) 2020-01-09
JP2020002019A5 true JP2020002019A5 (en) 2021-07-29

Family

ID=69098975

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018120081A Pending JP2020002019A (en) 2018-06-25 2018-06-25 Oral composition
JP2022072979A Active JP7463429B2 (en) 2018-06-25 2022-04-27 Oral Composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022072979A Active JP7463429B2 (en) 2018-06-25 2022-04-27 Oral Composition

Country Status (1)

Country Link
JP (2) JP2020002019A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6903306B1 (en) * 2020-07-28 2021-07-14 株式会社サン・クロレラ Oral composition for improving the barrier function of human keratinized epithelial cells in the oral cavity
CN115252459A (en) * 2022-07-28 2022-11-01 广州舒客实业有限公司 Oral cavity anti-sugar composition and application thereof in oral cavity care product

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05201843A (en) * 1992-01-29 1993-08-10 Pola Chem Ind Inc Composition for oral cavity application
JPH10182390A (en) * 1996-12-25 1998-07-07 Lion Corp Composition for oral cavity
CN1764468B (en) * 2003-04-11 2010-05-26 株式会社凤凰堂 Skin protecting composition
CN1832751B (en) * 2003-07-29 2010-05-26 株式会社凤凰堂 Periodontal disease therapeutic and/or preventive composition
US7754248B2 (en) * 2004-10-26 2010-07-13 Johnson & Johnson Consumer Companies, Inc. Ingestible compositions containing extracts
GB0614353D0 (en) * 2006-07-20 2006-08-30 Oraldent Ltd Oral compositions, their preparation and use
US20100121083A1 (en) * 2007-03-19 2010-05-13 Yuuzou Tsuchida Anti-viral agent
JP2010159240A (en) * 2009-01-09 2010-07-22 Takashi Kodera Composition having tissue or cell injury restoration ability and internal cleaning ability for mammal
JP5437692B2 (en) * 2009-04-30 2014-03-12 インターコンチネンタル グレート ブランズ エルエルシー Chewing gum composition, chewing gum product, and methods for producing them
JP6055623B2 (en) * 2012-07-25 2016-12-27 有限会社漢方歯科医学研究所 Periodontal disease prevention and treatment composition and cosmetic preservative
WO2014138897A1 (en) * 2013-03-14 2014-09-18 Anacoti Ltd. Hyaluronic acid derivatives

Similar Documents

Publication Publication Date Title
JP2014221842A5 (en)
JP2015522045A5 (en)
JP2015044981A5 (en)
WO2014191521A3 (en) New compact scaffold of cas9 in the type ii crispr system
JP2015158628A5 (en)
JP2012111226A5 (en)
JP2011238312A5 (en)
JP2016520672A5 (en)
JP2013510391A5 (en)
JP2015188307A5 (en)
JP2016139345A5 (en)
JP2014519537A5 (en)
JP2020002019A5 (en)
JP2016536436A5 (en)
JP2013540864A5 (en)
JP2013517350A5 (en)
IL283430B (en) Formulations comprising recombinant acid alpha-glucosidase
JP2020504434A5 (en)
JP2013531183A5 (en)
NZ725471A (en) Heat transfer fluids, systems, efficiencies, and methods
JP2012184414A5 (en)
JP2009055850A5 (en)
JP2018147822A5 (en)
JP2015528519A5 (en)
JP2016175963A5 (en)